For the Inventor, By the Inventor

Enter inventor name

Marburg, Germany

Klaus Bosslet

USPTO Granted Patents = 37

Average Co-Inventor Count = 3.8

ph-index = 13

Forward Citations = 1,110(Granted Patents)

Location History:

Gaithersburg, MD (US) (2000)
Marburg, DE (1996 - 2013)

Company Filing History:

Behringwerke Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Hoechst Aktiengesellschaft

Behring Diagnostics Gmbh

Laboratoires Hoechst S/a

6. 2 out of 149

Dade Behring Marburg Gmbh

Behringwerke Aktiengellschaft

Laboratories Hoechst S.a.

Laboratoires Hoechst

Behrinwerke Aktienegesellschaft

Heochst Aktiengesellschaft

12. 1 out of 18

Hoechst Marion Roussel Deutschland Gmbh

Behrinwerke Aktiengesellschaft

14. 1 out of 1,832

Sanofi-A Ventis Deutschland Gmbh

Sanofi-Aventis Pharma Deutschland Gmbh

where one patent can have more than one assignee

Years Active: 1996-2013

Loading Chart...

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8552159 - Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy (2013-10-08),

2. 7662383 - Chimeric antibody against tumor associated antigens and its use in diagnosing tumors (2010-02-16),

3. 7314753 - [object Object] (2008-01-01),

4. 7273727 - Fusion proteins for prodrug activation (2007-09-25),

5. 7241595 - Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates (2007-07-10),

6. 7060495 - Fusion proteins for prodrug activation (2006-06-13),

7. 6926896 - Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof (2005-08-09),

8. 6610299 - Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates (2003-08-26),

9. 6602688 - Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli (2003-08-05),

10. 6475486 - Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates (2002-11-05),

11. 6294172 - Monoclonal antibodies with specificity for membrane-associated antigens (2001-09-25),

12. 6146658 - Prodrugs, their preparation and use as pharmaceuticals (2000-11-14),

13. 6030797 - Monoclonal antibodies against tumor-associated antigens, processes for (2000-02-29),

14. 6020315 - Preparation having increased in vivo tolerability (2000-02-01),

15. 6008023 - Cytoplasmic expression of antibodies, antibody fragments and antibody (1999-12-28),

Title: The Innovative Mind of Klaus Bosslet

Introduction: Klaus Bosslet, a distinguished inventor hailing from Marburg, Germany, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Klaus Bosslet's recent patents showcase his expertise in developing cutting-edge solutions for various industries, including automotive, healthcare, and telecommunications.

Career Highlights: With a career spanning over two decades, Klaus Bosslet has established himself as a visionary inventor with a keen eye for identifying gaps in the market and creating innovative solutions to address them. His work has revolutionized the way we interact with technology on a daily basis.

Collaborations: Throughout his career, Klaus Bosslet has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work seamlessly in multidisciplinary teams has led to the successful implementation of numerous groundbreaking projects.

Conclusion: Klaus Bosslet's relentless passion for innovation and his unwavering commitment to pushing the boundaries of what is possible make him a true pioneer in the world of technology. His contributions have not only transformed industries but have also inspired a new generation of inventors to dream big and think outside the box.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…